Off-Label Drug Use Liability
Scholar argues that FDA approval should not save drug makers from state-law claims arising from off-label use.
How States Can Improve Contraceptive Access
A recent report proposes state-level reforms to allow pharmacists to prescribe contraceptives.
Small-Scale Solutions to the Large-Scale Drug Crisis
Expert advocates a variety of policies that local governments can take to combat increasing fatalities from drug overdoses.
HHS Selects Drugs for Medicare Price Negotiation
Biden Administration introduces price regulation to the pharmaceutical industry.
Patents Do Not Bar Public Pharma Policies
Merck misconstrues patent law in its recent Takings Clause challenge to Medicare’s price negotiation program.
FDA’s Role in Access to Reproductive Health Care
Recent abortion pill litigation underscores the significance of calls to make birth control pills available over the counter.
Regulating to Improve Methadone Access
Scholars identify avenues to curb regulatory barriers to substitution therapy.
Drug Safety, or Overregulation of Reproductive Health?
Scholar calls for FDA to remove stringent restrictions on medication abortion.
FDA, Not a Federal Judge, Should Decide on Abortion Drugs
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
Regulating Supervised Consumption Services
Experts discuss the role of regulations in monitoring experimental overdose prevention programs.
The ADA’s Power to Reduce Overdose Deaths in Prison
Scholars argue that the ADA’s protections could prevent overdose deaths for people in prison.
Hallucinate, Medicate, and Regulate
In this week’s Saturday Seminar, experts discuss ways to regulate psychedelics for medicinal use.